66 -8 (82) 2025 - Tursunov, son of J.Kh., Aripov A.N. - PATHOGENETIC MECHANISMS OF THE DEVELOPMENT OF RESTENOSIS AND STENT THROMBOSIS IN PATIENTS UNDERGROUND PERCUTANEOUS CORONARY INTERVENTION: INFLAMMATION, COAGULATION SYSTEM AND LIPID E

PATHOGENETIC MECHANISMS OF THE DEVELOPMENT OF RESTENOSIS AND STENT THROMBOSIS IN PATIENTS UNDERGROUND PERCUTANEOUS CORONARY INTERVENTION: INFLAMMATION, COAGULATION SYSTEM AND LIPID EXCHANGE FACTORS

Tursunov, son of J.Kh. - Andijan regional multidisciplinary medical center cardiology

Aripov A.N. - Republican Center for Specialized Pediatric Scientific and Applied Medicine, Head of Clinical Diagnostic Laboratory Department

Tursunov Kh.Kh. - Andijan State Medical Institute

Resume

This study investigated the pathogenetic mechanisms underlying restenosis and stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). A total of 307 patients were examined through clinical and laboratory assessments. Restenosis occurred in 11.3% and stent thrombosis in 3.3% of cases. Elevated inflammatory markers (CRP, fibrinogen), coagulation abnormalities (aPTT) and lipid metabolism disorders (elevated LDL-cholesterol) were identified as major risk factors. Comprehensive biomarker monitoring and individualized treatment strategies play a crucial role in preventing post-PCI complications.

Keywords: percutaneous coronary intervention, restenosis, stent thrombosis, inflammation, coagulation system, lipid metabolism, biomarkers.

First page

369

Last page

372

For citation:Tursunov, son of J.Kh., Aripov A.N., Tursunov Kh.Kh. - PATHOGENETIC MECHANISMS OF THE DEVELOPMENT OF RESTENOSIS AND STENT THROMBOSIS IN PATIENTS UNDERGROUND PERCUTANEOUS CORONARY INTERVENTION: INFLAMMATION, COAGULATION SYSTEM AND LIPID EXCHANGE FACTORS//New Day in Medicine 8(82)2025 369-372 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

1. Smith J, et al. Percutaneous Coronary Intervention Outcomes. Journal of the American College of Cardiology (JACC), 2020;75(14):1684–1696. https://doi.org/10.1016/j.jacc.2020.02.035
2. Kim Y, et al. Inflammation and Restenosis. Circulation, 2021;143(19):1903–1916. https://doi.org/10.1161/CIRCULATIONAHA.120.050123
3. European Society of Cardiology (ESC). 2022 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2022;43(34):2313–2401. https://doi.org/10.1093/eurheartj/ehac253
4. Patel R, et al. Biomarkers in Stent Thrombosis. Heart, 2019;105(14):1078–1084. https://doi.org/10.1136/heartjnl-2018-314521
5. Ridker PM, et al. Inflammatory Markers and Cardiovascular Risk. New England Journal of Medicine (NEJM), 2018;379:1119–1131. https://doi.org/10.1056/NEJMoa1804981
6. Lee S, et al. Coagulation Cascade and PCI Complications. Thrombosis Research, 2020;194:94–101. https://doi.org/10.1016/j.thromres.2020.06.018
7. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease.The Lancet, 2019;393(10166):1624–1635. https://doi.org/10.1016/S0140-6736%2818%2932594-6
8. World Health Organization. Global Health Statistics Report 2023. WHO, Geneva. https://www.who.int/data

   file

   download